文献速递糖尿病

FINEARTS-HF 中非奈利酮剂量-暴露-反应分析:血钾与心血管结局

Dose–Exposure–Response Analysis of Finerenone on Serum Potassium and Cardiovascular Outcomes Among Patients With Heart Failure: Insights From FINEARTS‐HF
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-11-04

基于 FINEARTS-HF 试验 6001 例 HFmrEF/HFpEF 患者,采用群体药代动力学/药效学及重复事件模型分析非奈利酮剂量对暴露、暴露对血钾、NT-proBNP 和复合终点的影响。结果显示剂量滴定可有效管理血钾,较高暴露与 NT-proBNP 显著降低相关,与复合终点降低无显著相关但模型提示暴露越高疗效越好。

要点

  • 非奈利酮剂量滴定策略可有效管理血清钾。
  • 较高药物暴露与 NT-proBNP 显著降低相关(p<0.001)。
  • 较高暴露与心血管复合终点降低无显著相关(p=0.55)。

核心结论

  • 在 FINEARTS-HF 中,非奈利酮剂量滴定能有效管理血清钾浓度。
  • 药代动力学/药效学模型提示较高非奈利酮暴露与改善心血管疗效相关。

研究设计与样本

  • FINEARTS-HF 试验随机分配 6001 例患者至非奈利酮或安慰剂组。
  • 非奈利酮初始及目标剂量根据基线 eGFR 和血钾滴定:eGFR≤60 时 10→20 mg,>60 时 20→40 mg。
  • 拟合非线性混合效应群体 PK/PD 及参数重复时间-事件模型。

主要发现

  • 初始剂量 10 mg 和 20 mg 组平均 eGFR 分别为 46±12 和 76±14 mL/min/1.73 m2。
  • 高钾血症(>5.5 mmol/L)频率在 10 mg 组为 4.3%、20 mg 组为 2.7%、40 mg 组为 1.5%。
  • 模拟无剂量滴定时,较高非奈利酮暴露产生更高血钾;模拟试验滴定策略后解释高暴露下低高钾血症频率。
  • 较高暴露与心血管复合事件频率降低无显著相关(p=0.55)。
  • 较高暴露导致 NT-proBNP 浓度显著更大程度降低(p<0.001)。

临床怎么用

  • 临床使用非奈利酮时应按基线 eGFR 和血钾进行剂量滴定以管理高钾血症风险。
  • 较高药物暴露可能带来更佳心血管获益,但需结合血钾监测。

局限性

  • FINEARTS-HF 并非设计用于随机比较剂量或暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Background Finerenone reduces the risk of heart failure and cardiovascular (CV) death among patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Whether the effects of finerenone to reduce CV risk are dose/exposure dependent is not clear. Methods In FINEARTS-HF, 6001 participants were randomized to finerenone or placebo, where the initial and target dose of finerenone was titrated according to the baseline estimated glomerular filtration rate (eGFR; 10– > 20 mg if baseline eGFR ≤ 60; 20– > 40 mg if > 60 mL/min/1.73 m2) and by serum potassium and changes in eGFR during the trial. We fitted non-linear mixed-effects population pharmacokinetic/pharmacodynamic and parametric repeated time-to-event models to explore the effect of finerenone dose on exposure (n = 6658 plasma concentration measurements) and exposure on serum potassium (n = 123 720 measurements), NT-proBNP (n = 16 971 measurements) and the primary composite outcome of total heart failure events and CV death (n = 2366 events). Results The mean eGFR in those with an initial dose of 10 mg and 20 mg was 46 ± 12 and 76 ± 14 mL/min/1.73 m2, respectively. The frequency of hyperkalemia (> 5.5 mmol/L) was 4.3% in patients taking 10 mg finerenone, 2.7% among those taking 20 mg and 1.5% among those taking 40 mg. Simulated PK/PD data produced higher serum potassium with higher finerenone exposure in a hypothetical scenario without dose titration; however, when simulating the protocol-guided dose titration strategy implemented in the trial, the lower observed frequency of hyperkalemia at higher finerenone exposure was explained. For the efficacy exposure–response analyses, while higher finerenone exposure was non-significantly related to a lower frequency of CV composite events (p = 0.55), higher exposure did result in a significantly greater reduction in NT-proBNP concentrations (p < 0.001). Conclusions Among participants of FINEARTS-HF, finerenone dose titration was effective in managing serum potassium concentration. Although FINEARTS-HF was not designed to test a randomized comparison of dose or exposure, the PK/PD model suggests that higher achieved exposure is associated with improved CV efficacy.

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Dose–Exposure–Response Analysis of Finerenone on Serum Potassium and Cardiovascular Outcomes Among Patients With Heart Failure: Insights From FINEARTS‐HF

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。